CDX2 and intrahepatic cholangiocarcinoma: Most of these entities are recognized by both WHO-HAEM5 and ICC (ALL/LBL with DUX4r, with MEF2Dr, with MYCr, with NUTM1r, with ZNF384r, with PAX5 alteration and with PAX5 p.80R), but a few are unique to the ICC classification (ALL/LBL “CDX2::UBTF”, ALL/LBL with IKZF1 p.N159Y, ALL/LBL with mutated ZEB2/IGH::CEBPE).